Atf3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ATF3 Gene
| Property | Value |
|----------|-------|
| **Gene Symbol** | ATF3 |
| **Full Name** | Activating Transcription Factor 3 |
| **Chromosomal Location** | 1q32.3 |
| **NCBI Gene ID** | 10566 |
| **OMIM ID** | 603148 |
| **Ensembl ID** | ENSG00000162771 |
| **UniProt ID** | Q9Y2T3 |
| **Associated Diseases** | Stroke, Neurodegeneration, Cancer, Wound Healing |
ATF3 (Activating Transcription Factor 3) encodes a stress-responsive transcription factor that belongs to the ATF/CREB family. ATF3 is rapidly induced by various cellular stresses and functions as both a transcriptional activator and repressor depending on context. It plays critical roles in cellular adaptation to stress, with complex roles in both neuroprotection and neurodegeneration. ATF3 is considered an "adaptive-response" gene that helps cells cope with environmental challenges.
ATF3 functions as:
- Stress-responsive transcription factor: Rapidly induced by cellular stress within 30-60 minutes
- Adaptive response gene: Promotes cell survival or death depending on context and intensity
- Transcriptional regulator: Binds to ATF/CRE sites in target gene promoters
- Immediate-early gene: Induced by cAMP, calcium, and growth factors
ATF3 can:
- Form homodimers or heterodimers with other ATF/CREB proteins
- Repress transcription when acting as a monomer (repressive domain)
- Activate transcription when forming heterodimers with c-Jun (AP-1 complex)
- Interact with histone deacetylases (HDACs) to modulate chromatin
ATF3 regulates numerous genes:
- Pro-survival: Bcl-2, Hsp27, GADD153/CHOP
- Pro-apoptotic: Bim, Puma, Noxa
- Inflammatory: cytokines, chemokines
- Metabolic: glucose transporters, metabolic enzymes
The ATF3 gene is located on chromosome 1q32.3 and spans approximately 12 kb. It encodes a 181-amino acid transcription factor with a basic leucine zipper (bZIP) DNA-binding domain. The gene contains multiple transcription start sites and is regulated by multiple promoters responsive to different stimuli.
The ATF3 protein contains:
- N-terminal regulatory domain: Contains transcription repression motifs (aa 1-100)
- bZIP domain: Basic region (aa 110-140) for DNA binding and leucine zipper (aa 140-175) for dimerization
- C-terminal region: Mediates protein-protein interactions
- Post-translational modifications: Phosphorylation, acetylation affect activity
¶ Stroke and Ischemia
ATF3 in cerebral ischemia:
- Rapid induction: ATF3 mRNA increases within hours of stroke
- Neuroprotective role: Exogenous ATF3 reduces infarct size in models
- Mechanism: Upregulation of anti-apoptotic and protective genes
- Therapeutic potential: ATF3 gene therapy approaches
ATF3 in neurodegenerative diseases:
- Alzheimer's disease: Elevated in neurons surrounding amyloid plaques
- Parkinson's disease: Induced in dopaminergic neurons
- ALS: Increased in motor neurons
- Dual role: Can be protective or detrimental depending on context
ATF3 in oncology:
- Tumor suppressor: Loss in some cancers correlates with progression
- Metastasis promoter: High ATF3 in some tumors enhances invasion
- Context-dependent: Role varies by cancer type
- Therapeutic target: Modulating ATF3 expression
ATF3 is expressed in:
- Brain: Neurons and glia, particularly in response to injury
- Heart: Cardiac myocytes in response to stress
- Liver: Hepatocytes, regulating metabolic genes
- Immune cells: T cells, macrophages during activation
- Most tissues: Low basal expression, highly inducible
ATF3 is regulated by:
- MAPK pathways: JNK, p38, ERK signaling
- cAMP/PKA pathway: Direct transcriptional activation
- Calcium signaling: Calmodulin-dependent pathways
- NF-κB pathway: Cross-talk with inflammatory signaling
ATF3 modulates:
- Chromatin accessibility: Through HDAC interactions
- RNA polymerase II: By recruiting co-activators or co-repressors
- Other TFs: Cross-talk with AP-1, CREB, NF-κB
| Strategy |
Approach |
Status |
Notes |
| Gene therapy |
AAV-ATF3 delivery |
Preclinical |
Neuroprotective in stroke models |
| Small molecules |
ATF3 modulators |
Discovery |
Limited by complexity |
| Biomarker |
ATF3 as stroke biomarker |
Research |
Blood ATF3 levels |
| Combination |
ATF3 + growth factors |
Preclinical |
Enhanced neuroprotection |
- Atf3 knockout mice: Viable with altered stress responses
- Transgenic ATF3 mice: Used to study neuroprotection
- Stroke models: ATF3 overexpression reduces damage
- Cancer models: Role in tumor progression studied
- Stroke therapy: Developing ATF3-based neuroprotective strategies
- Selective modulation: Achieving cell-type specific effects
- Biomarker development: ATF3 as diagnostic/prognostic marker
- Mechanism elucidation: Understanding context-dependent roles
- Drug discovery: Targeting ATF3-regulating pathways
The study of Atf3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hai T, et al. "ATF3 and stress responses." Gene Expr 2022.
- Thompson MR, et al. "ATF3 in stroke and neuroprotection." J Cereb Blood Flow Metab 2021.
- Ku HC, Cheng CF. "ATF3 in neurodegeneration." Cell Mol Neurobiol 2020.
- Janaki Ramaiah M, et al. "ATF3 in cancer therapy." Cancer Lett 2019.
- Liang G, et al. "ATF3 structure and function." Biochim Biophys Acta 2018.